Chesebro Jh
About
In The Last Decade
Chesebro Jh
22 papers receiving 480 citations
Peers
Comparison fields: 5 of 65
- Cardiology and Cardiovascular Medicine 326
- Surgery 235
- Pulmonary and Respiratory Medicine 102
- Epidemiology 83
- Radiology, Nuclear Medicine and Imaging 63
Countries citing papers authored by Chesebro Jh
This map shows the geographic impact of Chesebro Jh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chesebro Jh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chesebro Jh more than expected).
Fields of papers citing papers by Chesebro Jh
This network shows the impact of papers produced by Chesebro Jh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chesebro Jh. The network helps show where Chesebro Jh may publish in the future.
Co-authorship network of co-authors of Chesebro Jh
This figure shows the co-authorship network connecting the top 25 collaborators of Chesebro Jh. A scholar is included among the top collaborators of Chesebro Jh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chesebro Jh. Chesebro Jh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Treatment of arterial thrombosis with low molecular weight heparins. | 2 |
| 2 | Wall passivation for unstable angina. | 2 |
| 3 | Cell biology of restenosis post-angioplasty. | 8 |
| 4 | Special report: cardiovascular disease in women. Special writing group. | 10 |
| 5 | Treatment of arterial thromboembolic disease. | 1 |
| 6 | Coronary atherosclerosis. A multifactorial disease. | 144 |
| 7 | Antithrombotic therapy for patients with cardiac disease. | 9 |
| 8 | Role of platelets in atherogenesis: relevance to coronary arterial restenosis after angioplasty. | 25 |
| 9 | Pathogenesis and prevention of aortocoronary bypass graft occlusion. | 5 |
| 10 | Antithrombotic therapy for acute myocardial infarction: mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism. | 24 |
| 11 | Coronary artery bypass grafting. A model for the understanding of the progression of atherosclerotic disease and the role of pharmacological intervention. | 3 |
| 12 | Systemic thromboembolism in valvular heart disease and prosthetic heart valves. | 36 |
| 13 | Evaluation of platelet-inhibitor drugs in a canine bilateral femoral graft implant model. | 10 |
| 14 | Systemic thromboembolism in mitral and aortic Starr-Edwards prostheses: a 10-19 year follow-up. | 77 |
| 15 | Drug trials in prevention of occlusion of aorta--coronary artery vein grafts. | 24 |
| 16 | A prospective study of peripheral occlusive arterial disease in diabetes. II. Vascular laboratory assessment. | 24 |
| 17 | 10. Antithrombotic therapy: role of platelet-inhibitor drugs. II. Pharmacologic effects of platelet-inhibitor drugs (second of three parts). | 18 |
| 18 | Antithrombotic therapy: role of platelet-inhibitor drugs. I. Current concepts of thrombogenesis: role of platelets. (first of three parts). | 39 |
| 19 | Series on pharmacology in practice. 10. Antithrombotic therapy: role of platelet-inhibitor drugs. III. Management of arterial thromboembolic and atherosclerotic disease (third of three parts). | 7 |
| 20 | Complete occlusion of the left main coronary artery and the importance of coronary collateral circulation. | 40 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.